Trials / Completed
CompletedNCT01009216
A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid
A Study to Evaluate the Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-384 in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Abbott · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The objectives of this study are to assess the cerebral spinal fluid (CSF) pharmacokinetics and the plasma/CSF pharmacokinetic/pharmacodynamic relationship of ABT-384 in healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-384 | Doses will be administered daily for 5 days. |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2009-11-06
- Last updated
- 2010-12-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01009216. Inclusion in this directory is not an endorsement.